How vitreomacular interface modifies the efficacy of anti-VEGF therapy for myopic choroidal neovascularization
Retina Jan 25, 2018
Iacono P, et al. - Authors intended to investigate the adequacy of intravitreal ranibizumab in the treatment of myopic choroidal neovascularization (mCNV) complicated by vitreoretinal interface alterations. Ranibizumab was discovered to be efficacious in controlling mCNV activity when associated with vitreoretinal interface alterations. Only patients with uncomplicated mCNV reported visual recovery.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
